Thaler Christian, Tokareva Bogdana, Wentz Rabea, Heitkamp Christian, Bechstein Matthias, van Horn Noel, Geest Vincent, Dührsen Lasse, Meyer Hanno S, Bester Maxim, Fiehler Jens, Meyer Lukas
From the Department of Diagnostic and Interventional Neuroradiology (C.T., B.T., C.H., M.B., N.v.H., V.G., M.B., J.F., L.M.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
From the Department of Diagnostic and Interventional Neuroradiology (C.T., B.T., C.H., M.B., N.v.H., V.G., M.B., J.F., L.M.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
AJNR Am J Neuroradiol. 2025 Mar 4;46(3):495-501. doi: 10.3174/ajnr.A8511.
Cerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be considered when conservative treatment options are exhausted, but its superiority over standard treatment remains a subject of critical debate. This study focuses on patients with clinically relevant vasospasm after aSAH who underwent endovascular vasospasm treatment and aims to analyze patients' individual risk factors, intensity, and extent of cerebral vasospasm associated with poor functional outcomes after aSAH.
We conducted a retrospective cohort study of consecutive patients with aSAH admitted at a tertiary stroke center between January 2016 and December 2022. Patients with medically refractory cerebral vasospasm necessitating at least 1 endovascular intervention were analyzed. Primary end point was defined as functional outcome defined as modified Rankin Scale (mRS) scores after 6 months. Secondary end point was the occurrence of cerebral infarctions following cerebral vasospasm.
Overall, 138 patients received endovascular treatment due to cerebral vasospasm, including 322 treatments, with 78 patients receiving more than 1 endovascular treatment. In 65.2% (90) of patients, cerebral vasospasm developed in both hemispheres; in 16.7% (23), cerebral vasospasm occurred involving the posterior circulation; and in 10.1% (14), percutaneous transluminal angioplasty was performed. Multivariable logistic regression analysis showed an association of higher age (adjusted odds ratio [aOR], 1.05, 95% CI: 1.0-1.1), higher Hunt and Hess grades (aOR, 2.12, 95% CI: 1.38-3.24), the occurrence of rebleeding (aOR, 4.97, 95% CI: 1.0-24.65), and bihemispheric vasospasm (aOR, 4.05, 95% CI: 1.4-11.72) with unfavorable outcome (mRS 3-6). Further analysis showed that higher age (aOR, 1.07, 95% CI: 1.03-1.13) was associated with an increased risk of developing vasospasm-associated infarctions.
Our results indicate an association between bihemispheric cerebral vasospasm and poor functional outcomes after aSAH. This finding supports a more aggressive treatment strategy in patients developing bihemispheric vasospasm to prevent unfavorable disease courses.
脑血管痉挛仍然是动脉瘤性蛛网膜下腔出血(aSAH)后预后不良的有力预测指标。当保守治疗方法用尽时,可以考虑对血管痉挛进行血管内治疗,但其相对于标准治疗的优越性仍是一个备受争议的话题。本研究聚焦于aSAH后发生具有临床相关性血管痉挛且接受了血管内血管痉挛治疗的患者,旨在分析患者的个体危险因素、脑血管痉挛的强度和范围与aSAH后功能预后不良的相关性。
我们对2016年1月至2022年12月期间在一家三级卒中中心收治的连续aSAH患者进行了一项回顾性队列研究。分析了因药物治疗难治性脑血管痉挛而需要至少1次血管内干预的患者。主要终点定义为6个月后改良Rankin量表(mRS)评分所定义的功能预后。次要终点是脑血管痉挛后发生脑梗死的情况。
总体而言,138例患者因脑血管痉挛接受了血管内治疗,包括322次治疗,其中78例患者接受了不止1次血管内治疗。在65.2%(90例)的患者中,双侧半球均发生了脑血管痉挛;在16.7%(23例)的患者中,脑血管痉挛发生在后循环;在10.1%(14例)的患者中,进行了经皮腔内血管成形术。多变量逻辑回归分析显示,年龄较大(调整后的优势比[aOR],1.05,95%置信区间[CI]:1.0 - 1.1)、Hunt和Hess分级较高(aOR,2.12,95% CI:1.38 - 3.24)、再出血的发生(aOR,4.97,95% CI:1.0 - 24.65)以及双侧半球血管痉挛(aOR,4.05,95% CI:1.4 - 11.72)与不良预后(mRS 3 - 6)相关。进一步分析表明,年龄较大(aOR,1.07,95% CI:1.03 - 1.13)与发生血管痉挛相关梗死的风险增加有关。
我们的结果表明双侧半球脑血管痉挛与aSAH后功能预后不良之间存在关联。这一发现支持对发生双侧半球血管痉挛的患者采取更积极的治疗策略,以预防不良病程。